ACE2, a new regulator of the renin-angiotensin system

被引：258

作者：

Burrell, LM ^{[1
]}

Johnston, CI

Tikellis, C

Cooper, ME

机构：

[1] Univ Melbourne, Dept Med, Austin Hlth, Heidelberg Hts, Vic 3081, Australia

[2] Baker Heart Res Inst, Melbourne, Vic 8088, Australia

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2004年 / 15卷 / 04期

关键词：

D O I：

10.1016/j.tem.2004.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Angiotensin-converting enzyme (ACE) is a zinc metalloproteinase and a key regulator of the renin-angiotensin system (RAS). ACE2 is a newly described enzyme identified in rodents and humans with a more restricted distribution than ACE, and is found mainly in heart and kidney. ACE2 cleaves a single residue from angiotensin I (Ang I) to generate Ang 1-9, and degrades Ang II, the main effector of the RAS, to the vasodilator Ang 1-7. The importance of ACE2 in normal physiology and pathophysiological states is largely unknown. ACE2 might act in a counter-regulatory manner to ACE, modulating the balance between vasoconstrictors and vasodilators within the heart and kidney, and playing a significant role in regulating cardiovascular and renal function.

引用

页码：166 / 169

页数：4

共 29 条

[1] Cardiac angiotensin-(1-7) in ischemic cardiomyopathy
Averill, DB
Ishiyama, Y
Chappell, MC
Ferrario, CM
[J]. CIRCULATION, 2003, 108 (17) : 2141 - 2146
[2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
Brenner, BM
Cooper, ME
de Zeeuw, D
Keane, WF
Mitch, WE
Parving, HH
Remuzzi, G
Snapinn, SM
Zhang, ZX
Shahinfar, S
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
[3] Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction
Chen, MM
Ashley, EA
Deng, DXF
Tsalenko, A
Deng, A
Tabibiazar, R
Ben-Dor, A
Fenster, B
Yang, E
King, JY
Fowler, M
Robbins, R
Johnson, FL
Bruhn, L
McDonagh, T
Dargie, H
Yakhini, Z
Tsao, PS
Quertermous, T
[J]. CIRCULATION, 2003, 108 (12) : 1432 - 1439
[4] Angiotensin-converting enzyme 2 is an essential regulator of heart function
Crackower, MA
Sarao, R
Oudit, GY
Yagil, C
Kozieradzki, I
Scanga, SE
Oliveira-dos-Santos, AJ
da Costa, J
Zhang, LY
Pei, Y
Scholey, J
Ferrario, CM
Manoukian, AS
Chappell, MC
Backx, PH
Yagil, Y
Penninger, JM
[J]. NATURE, 2002, 417 (6891) : 822 - 828
[5] Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors
Dales, NA
Gould, AE
Brown, JA
Calderwood, EF
Guan, B
Minor, CA
Gavin, JM
Hales, P
Kaushik, VK
Stewart, M
Tummino, PJ
Vickers, CS
Ocain, TD
Patane, MA
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2002, 124 (40) : 11852 - 11853
[6] The secret life of ACE2 as a receptor for the SARS virus
Dimitrov, DS
[J]. CELL, 2003, 115 (06) : 652 - 653
[7] A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
Donoghue, M
Hsieh, F
Baronas, E
Godbout, K
Gosselin, M
Stagliano, N
Donovan, M
Woolf, B
Robison, K
Jeyaseelan, R
Breitbart, RE
Acton, S
[J]. CIRCULATION RESEARCH, 2000, 87 (05) : E1 - E9
[8] Heart block, ventricular tachycardia, and sudden death in ACE2 transgenic mice with downregulated connexins
Donoghue, M
Wakimoto, H
Maguire, CT
Acton, S
Hales, P
Stagliano, N
Fairchild-Huntress, V
Xu, J
Lorenz, JN
Kadambi, V
Berul, CI
Breitbart, RE
[J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (09) : 1043 - 1053
[9] Vasoactive potential of the B1 bradykinin receptor in normotension and hypertension
Duka, I
Kintsurashvili, E
Gavras, I
Johns, C
Bresnahan, M
Gavras, H
[J]. CIRCULATION RESEARCH, 2001, 88 (03) : 275 - 281
[10] Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction
Duncan, AM
Burrell, LM
Kladis, A
Campbell, DJ
[J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (06) : 746 - 754

← 1 2 3 →